European evidence-based consensus: Inflammatory bowel disease and malignancies

Journal of Crohn's and Colitis

Volumn 9, Issue 11, 2015, Pages 945-965

  Annese, Vito ^a   Beaugerie, Laurent ^b   Egan, Laurence ^c   Biancone, Livia ^d   Bolling, Claus ^e   Brandts, Christian ^f   Dierickx, Daan ^g   Dummer, Reinhard ^h   Fiorino, Gionata ⁱ   Gornet, Jean Marc ^j   Higgins, Peter ^k   Katsanos, Konstantinos H ^l   Nissen, Loes ^m   Pellino, Gianluca ⁿ   Rogler, Gerhard ^o   Scaldaferri, Franco ^p   Szymanska, Edyta ^q   Eliakim, Rami ^r   Bossuyt, P ^s   Bogut, A ^s   Krznaric, Z ^s   Mijandrusic Sincic, B ^s   Bortlik, M ^s   Douda, T ^s   Knudsen, T ^s   Manninen, P ^s   Nieminen, U ^s   Kucharzik, T ^s   Siegmund, B ^s   Koutroubakis, I ^s   Epameinondas, T ^s   Lakatos, P ^s   Waterman, M ^s   Kohn, A ^s   Goll, ^s   Kierkus, J ^s   Zagorowicz, E ^s   Diculescu, M M ^s   Tarabar, D ^s   Drobne, D ^s   Gisbert, J ^s   Strid, H ^s   Pierik, M ^s   Celik, A F ^s   Irving, P ^s   Marshall, J ^s   Riis, L ^s   Amiot, A ^s   Mantzaris, G ^s   Sinagra, E ^s   Selvaggi, F ^s   Sampietro, G ^s   D'Inca R ^s   De Ridder, L ^s   Nunesl, P B ^s   Marin Jimenez, I ^s   Ramirez, V H ^s   Juillerat, P ^s   Claridge, A ^s   Macdonald, J ^s   Rieder, F ^s   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b HÔPITAL SAINT ANTOINE   (France)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e AGAPLESION MARKUS KRANKENHAUS   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j SAINT LOUIS HOSPITAL   (France)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF IOANNINA   (Greece)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^p CATHOLIC UNIVERSITY   (Italy)

^q CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^r SHEBA MEDICAL CENTER   (Israel)

^s NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADVANCED CANCER; AGE; ANUS FISTULA; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CARCINOID; CHRONIC DISEASE; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSENSUS; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG INDUCED CANCER; DRUG WITHDRAWAL; DYSPLASIA; ENTEROCUTANEOUS FISTULA; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FEVER; GASTROINTESTINAL STROMAL TUMOR; GENDER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOSPLENIC T CELL LYMPHOMA; HEPATOSPLENOMEGALY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; ILEOANAL ANASTOMOSIS; INFLAMMATORY BOWEL DISEASE; LYMPHADENOPATHY; LYMPHOMA; MALIGNANT TRANSFORMATION; MEDICAL HISTORY; MELANOMA; META ANALYSIS (TOPIC); NON MELANOMA SKIN CANCER; ONSET AGE; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POST MONONUCLEOSIS LYMPHOMA; POST TRANSPLANT LIKE LYMPHOMA; PREOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; RISK REDUCTION; SKIN CANCER; SKIN EXAMINATION; SMALL INTESTINE CANCER; SMALL INTESTINE OBSTRUCTION; SUN EXPOSURE; SYSTEMATIC REVIEW (TOPIC); T CELL LYMPHOMA; ULCERATIVE COLITIS; URINARY TRACT CANCER; UTERINE CERVIX CANCER; COMPLICATION; CONSENSUS DEVELOPMENT; EUROPE; EVIDENCE BASED MEDICINE; INFLAMMATORY BOWEL DISEASES; MORTALITY; NEOPLASMS; PATHOLOGY; PROGNOSIS; RISK FACTOR;

EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84963761365     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv141     Document Type: Article

References (253)

1. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-83
2. CEBM. Center for Evidence-Based Medicine. Universiy of Oxford. http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf Accessed August 25, 2015
3. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-9
4. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45
5. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8
6. Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-99
7. Annese V, Daperno M, Rutter MD, et al. European Evidencebased Consensus for endoscopy in inflammatory bowel disease. J Crohn's Colitis 2013;7:982-1018
8. Itzkowitz SH, Present DH, Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-21
9. Borjesson L, Willen R, Haboubi N, et al. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. Colorect Dis 2004;6:494-8
10. M'Koma AE, Moses HL, Adunyah SE. Inflammatory bowel diseaseassociated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. Int J Colorect Dis 2011;26:533-52
11. Tysk C, Schnurer LB, Wickbom G. Obstructing inflammatory fibroid polyp in pelvic ileal reservoir after restorative proctocolectomy in ulcerative colitis. Report of a case. Dis Colon Rectum 1994;37:1034-7
12. Ziv Y, Fazio VW, Strong SA, et al. Ulcerative colitis and coexisting colorectal cancer: recurrence rate after restorative proctocolectomy. Ann Surg Oncol 1994;1:512-5
13. Watanabe T, Konishi T, Kishimoto J, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 2011;17:802-8
14. Hrabe JE, Byrn JC, Button AM, et al. A matched case-control study of IBD-associated colorectal cancer: IBD portends worse outcome. J Surg Oncol 2014;109:117-21
15. Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis 2013;19:800-5
16. Ali RAR, Dooley C, Comber H, et al. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:584-9.e1-2
17. Scharl M, Frei P, Frei SM, et al. Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. Eur J Gastroenterol Hepatol 2014;26:114-8
18. Sogawa M, Watanabe K, Egashira Y, et al. Precise endoscopic and pathologic features in a Crohn's disease case with two fistula-associated small bowel adenocarcinomas complicated by an anal canal adenocarcinoma. Intern Med 2013;52:445-9
19. Ying LT, Hurlbut DJ, Depew WT, et al. Primary adenocarcinoma in an enterocutaneous fistula associated with Crohn's disease. Can J Gastroenterol 1998;12:265-9
20. Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 2011;15:576-83
21. Baars JE, Kuipers EJ, Dijkstra G, et al. Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands. Scand J Gastroenterol 2011;46:319-25
22. Moore-Maxwell CA, Robboy SJ. Mucinous adenocarcinoma arising in rectovaginal fistulas associated with Crohn's disease. Gynecol Oncol 2004;93:266-8
23. Smith R, Hicks D, Tomljanovich PI, et al. Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature. Am Surg 2008;74:59-61
24. Winkler R, Wittmer A, Heusermann U. [Cancer and Crohn's disease]. Z Gastroenterol 2002;40:569-76
25. Thomas M, Bienkowski R, Vandermeer TJ, et al. Malignant transformation in perianal fistulas of Crohn's disease: a systematic review of literature. J Gastrointest Surg 2010;14:66-73
26. Devroe H, Coene L, Mortelmans LJ, et al. Colloid carcinoma arising in an anorectal fistula in Crohn's disease: a case report. Acta Chir Belg 2005;105:110-1
27. Iesalnieks I, Gaertner WB, Glass H, et al. Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis 2010;16:1643-8
28. Devon KM, Brown CJ, Burnstein M, et al. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum 2009;52:211-6
29. Ficari F, Fazi M, Garcea A, et al. Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori 2005;4:S31
30. Ky A, Sohn N, Weinstein MA, et al. Carcinoma arising in anorectal fistulas of Crohn's disease. Dis Colon Rectum 1998;41:992-6
31. Laurent S, Barbeaux A, Detroz B, et al. Development of adenocarcinoma in chronic fistula in Crohn's disease. Acta Gastroenterol Belg 2005;68:98-100
32. Panier-Suffat L, Marracino M, Resegotti A, et al. Anal transitional zone adenocarcinoma following restorative proctocolectomy for ulcerative colitis: case report and review of literature. Acta Gastroenterol Belg 2009;72:441-3
33. Zmora O, Spector D, Dotan I, et al. Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer? Int J Colorectal Dis 2009;24:1181-6
34. Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology 2010;139:806-12, 812 e1-2
35. Scarpa M, van Koperen PJ, Ubbink DT, et al. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007;94:534-45
36. Branco BC, Sachar DB, Heimann TM, et al. Adenocarcinoma following ileal pouch-anal anastomosis for ulcerative colitis: review of 26 cases. Inflamm Bowel Dis 2009;15:295-9
37. Derikx LA, Kievit W, Drenth JP, et al. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. Gastroenterology 2014;146:119-28 e1
38. Vento P, Lepisto A, Karkkainen P, et al. Risk of cancer in patients with chronic pouchitis after restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2011;13:58-66
39. Hernandez JD, Jimenez-Huyke C, Rosado K, et al. Surveillance for dysplasia in patients with ileal pouch-anal anastomosis for ulcerative colitis: an interim analysis. Dig Dis Sci 2010;55:2332-6
40. Das P, Johnson MW, Tekkis PP, et al. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2007;9:15-27
41. Johnson WR, McDermott FT, Hughes ES, et al. The risk of rectal carcinoma following colectomy in ulcerative colitis. Dis Colon Rectum 1983;26:44-6
42. Campos FG, Teixeira MG, Scanavini A, et al. Intestinal and extraintestinal neoplasia in patients with inflammatory bowel disease in a tertiary care hospital. Arq Gastroenterol 2013;50:123-9
43. Freeman HJ. Appendiceal carcinoids in Crohn's disease. Can J Gastroenterol 2003;17:43-6
44. Hemminki K, Li X, Sundquist J, et al. Cancer risks in ulcerative colitis patients. Int J Cancer 2008;123:1417-21
45. Peneau A, Savoye G, Turck D, et al. Mortality and cancer in pediatriconset inflammatory bowel disease: a population-based study. Am J Gastroenterol 2013;108:1647-53
46. Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis 2014;46:97-104
47. Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994;1:290-5
48. Elriz K, Carrat F, Carbonnel F, et al. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis 2013;19:1823-6
49. Hernandez V, Clofent J. Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. Ann Gastroenterol 2012;25:193-200
50. Egan L, D'Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [II]. J Crohns Colitis 2014;8:19-30
51. Piton G, Cosnes J, Monnet E, et al. Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol 2008;103:1730-6
52. Boltin D, Levi Z, Halpern M, et al. Concurrent small bowel adenocarcinoma and carcinoid tumor in Crohn's disease-case report and literature review. J Crohns Colitis 2011;5:461-4
53. Drukker L, Edden Y, Reissman P. Adenocarcinoma of the small bowel in a patient with occlusive Crohn's disease. World J Gastrointest Oncol 2012;4:184-6
54. Genta RM, Feagins LA. Advanced precancerous lesions in the small bowel mucosa. Best Pract Res Clin Gastroenterol 2013;27:225-33
55. Jess T, Horvath-Puho E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013;108:1869-76
56. Kamiya T, Ando T, Ishiguro K, et al. Intestinal cancers occurring in patients with Crohn's disease. J Gastroenterol Hepatol 2012;27 Suppl 3:103-7
57. Lakatos PL, David G, Pandur T, et al. Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008. J Crohns Colitis 2011;5:122-8
58. Nihon-Yanagi Y, Ooshiro M, Yamada A, et al. Abdominal wall infiltration by small bowel adenocarcinoma in a patient with Crohn's disease-a case report. Gan To Kagaku Ryoho 2011;38:1011-6
59. Reynolds I, Healy P, McNamara DA. Malignant tumours of the small intestine. Surgeon 2014;12:263-70
60. Shaukat A, Virnig DJ, Howard D, et al. Crohn's disease and small bowel adenocarcinoma: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2011;20:1120-3
61. Svrcek M, Piton G, Cosnes J, et al. Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study. Inflamm Bowel Dis 2014;20:1584-92
62. Weber NK, Fletcher JG, Fidler JL, et al. Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn's disease. Abdom Imaging 2015;40:1060-7
63. Zagorowicz ES, Pietrzak AM, Wronska E, et al. Small bowel tumors detected and missed during capsule endoscopy: single center experience. World J Gastroenterol 2013;19:9043-8
64. Place V, Hristova L, Dray X, et al. Ileal adenocarcinoma in Crohn's disease: magnetic resonance enterography features. Clin Imaging 2012;36:24-8
65. Tirkes AT, Duerinckx AJ. Adenocarcinoma of the ileum in Crohn disease. Abdom Imaging 2005;30:671-3
66. Kerber GW, Frank PH. Carcinoma of the small intestine and colon as a complication of Crohn disease: radiologic manifestations. Radiology 1984;150:639-45
67. Castro FA, Liu X, Forsti A, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol 2014;12:1038-45 e7
68. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a populationbased case-control study. Clin Gastroenterol Hepatol 2007;5:1221-8
69. Erichsen R, Jepsen P, Vilstrup H, et al. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009;24:513-20
70. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007;120:638-41
71. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84
72. Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet 2013;382:1587-99
73. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12
74. Kaiser AM, Kang JC, Tolazzi AR, et al. Primary solitary extragastrointestinal stromal tumor of the greater omentum coexisting with ulcerative colitis. Dig Dis Sci 2006;51:1850-2
75. Grieco A, Cavallaro A, Potenza AE, et al. Gastrointestinal stromal tumor [GIST] and ulcerative colitis. J Exp Clin Cancer Res 2002;21:617-20
76. Pfeffel F, Stiglbauer W, Depisch D, et al. Coincidence of Crohn's disease and a high-risk gastrointestinal stromal tumor of the terminal ileum. Digestion 1999;60:363-6
77. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-7
78. Biancone L, Zuzzi S, Ranieri M, et al. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis 2012;6:578-87
79. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis 2009;15:1621-9
80. Sebastian S, Hernandez V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop [I]. J Crohns Colitis 2014;8:5-18
81. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [III]. J Crohns Colitis 2014;8:31-44
82. SEER. National Cancer Institute. Surveillance, Epidemiology and End Results. SEER training modules: Cancer Registration. 2014. http://seer.cancer.gov/statfacts/Accessed May 30, 2014
83. Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2063-71
84. Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013;48:9
85. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22
86. Bernstein C, Blanchard JF, Kliewer E, et al. Cancer Risk in Patients with Inflammatory Bowel Disease. A Population-Based Study. Cancer 2001;15:9
87. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007;50:839-55
88. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822-8
89. Johnson KJ, Blair CM, Fink JM, et al. Medical conditions and risk of adult myeloid leukemia. Cancer Causes Control 2012;23:1083-9
90. Mir-Madjlessi SH, Farmer RG, Easley KA, et al. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer 1986;58:6
91. Viscido A, Bagnardi V, Sturniolo GC, et al. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig Liver Dis 2001;33:7
92. de Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the Porto Pediatric IBD group. Inflamm Bowel Dis 2014;20:291-300
93. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701
94. Harewood GC, Loftus EV Jr, Tefferi A, et al. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis 1999;5:6
95. Arseneau KO, Stukenborg GJ, Connors AF Jr, et al. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis 2001;7:7
96. Gidrewicz D, Lehman D, Rabizadeh S, et al. Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease. J Pediatr Gastroenterol Nutr 2011;52:3
97. Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2013;19:1384-9
98. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr viruspositive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 2000;24:8
99. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011;17:1837-45
100. Crispino P, Pica R, Angelucci E, et al. Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int J Colorectal Dis 2007;22:553-8
101. Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO [I]: Pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014;8:1147-65
102. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006;134:4
103. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor [TNF] and lymphotoxin-alpha [LTA] polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010;171:267-76
104. Kast RE, Altschuler EL. Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha. Arch Immunol Ther Exp [Warsz] 2005;53:5
105. Guitart J, Deonizio J, Bloom T, et al. High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas. JAMA Dermatol 2014;150:7
106. Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 2013;28:24-30
107. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299-307
108. Hebbar M, Kozlowski D, Wattel E, et al. Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia 1997;11:4
109. Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large singlecenter cohort. Inflamm Bowel Dis 2012;18:838-43
110. Sorensen GV, Erichsen R, Svaerke C, et al. Risk of cancer in patients with inflammatory bowel disease and venous thromboembolism: a nationwide cohort study. Inflamm Bowel Dis 2012;18:1859-63
111. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:10
112. Duong HK, Savani BN, Copelan E, et al. Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014;20:1262-73
113. Musso M, Porretto F, Crescimanno A, et al. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant 2000;26:3
114. Robinson JK. Sun exposure, sun protection, and vitamin D. JAMA 2005;294:4
115. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-74
116. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-399 e1
117. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-20
118. Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep 2013;15:310
119. Lanoy E, Engels EA. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer 2010;103:112-4
120. Candel S, de Oliveira S, Lopez-Munoz A, et al. Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation. PLoS Biol 2014;12:e1001855
121. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology 2011;141:1621-8.e5
122. Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immunemediated inflammatory diseases [IMID]. Mol Cancer 2013;12:98
123. Ortiz A, Grando SA. Smoking and the skin. Int J Dermatol 2012;51:13
124. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4
125. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:6
126. Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families. J Nat Cancer Inst 2004;96:785-95
127. Owens DW, Lane EB. Keratin mutations and intestinal pathology. J Pathol 2004;204:377-85
128. Owens DW, Wilson NJ, Hill AJ, et al. Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. J Cell Sci 2004;117:11
129. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012;61:476-83
130. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med 2015;372:1441-52
131. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006;79-80:153-70
132. Harwood CA, Attard NR, O'Donovan P, et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer 2008;99:1276-84
133. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167-98
134. Munz C, Moormann A. Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol 2008;18:381-7
135. Lopez A, Mounier M, Bouvier AM, et al. Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2014;12:132-49
136. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-8
137. Camus M, Seksik P, Bourrier A, et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013;11:389-94
138. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52
139. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32
140. Gomez-Garcia M, Cabello-Tapia MJ, Sanchez-Capilla AD, et al. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain. World J Gastroenterol 2013;19:4877-86
141. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53
142. Warman JI, Korelitz BI, Fleisher MR, et al. Cumulative experience with short-and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003;37:220-5
143. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105:1604-9
144. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-23
145. Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296-305
146. Fiocchi C. Closing fistulas in Crohn's disease-should the accent be on maintenance or safety? N Engl J Med 2004;350:934-6
147. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406-13
148. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
149. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58
150. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-9
151. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33
152. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011;17:758-66
153. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-7; quiz 1176
154. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given antitumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5
155. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
156. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. Am J Gastroenterol 2014;109:212-23
157. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
158. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35
159. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4
160. Bologna C, Viu P, Picot MC, et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997;36:535-40
161. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010;16:837-46
162. Wimmer CD, Angele MK, Schwarz B, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int 2013;26:999-1006
163. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
164. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6
165. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006;19:607-20
166. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of Lymphoma in Patients with Inflammatory Bowel Disease Treated with Azathioprine and 6-Mercaptopurine: a Meta-Analysis. Clin Gastroenterol Hepatol 2015;13:847-58
167. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146-53
168. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007-15 e3
169. Lakatos PL, Lovasz BD, David G, et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91
170. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:6
171. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9
172. Van Domselaar M, Lopez San Roman A, Bastos Oreiro M, et al. [Lymphoproliferative disorders in an inflammatory bowel disease unit]. Gastroenterol Hepatol 2010;33:12-6
173. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
174. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15
175. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-30
176. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22 Suppl 1:i4-10
177. Beaugerie L. Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 2013;145:927-30
178. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon, France: International Agency for Research on Cancer, 2008
179. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 [XLP-1/SAP deficiency] versus type 2 [XLP-2/XIAP deficiency]. Blood 2011;117:1522-9
180. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
181. Weinstock DM, Ambrossi GG, Brennan C, et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539-46
182. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in highrisk patients. Blood 2001;97:1165-71
183. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-9
184. Serrate C, Silva-Moreno M, Dartigues P, et al. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome com plicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis 2009;15:1449-51
185. Biank VF, Sheth MK, Talano J, et al. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011;159:808-12
186. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8 e5
187. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
188. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014;109:163-9
189. Abbas AM, Almukhtar RM, Loftus EV Jr, et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014;109:1781-93
190. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904
191. Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993;32 Suppl 1:72-5
192. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2014;12:210-8
193. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, et al. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol 2012;107:1443-4
194. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9
195. Dahlke E, Murray CA, Kitchen J, et al. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res 2014;3:10
196. Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat 2012;23:290-304
197. Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:598-605
198. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009;136:451-8
199. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-6
200. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2015;74:1360-74
201. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12:6167-71
202. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62
203. Rahier JF, Magro F, Abreu C, et al. Second European Evidence-based Consensus on the prevention, diagnosis, and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-68
204. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91
205. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742-7
206. Quinn MJ, d'Onofrio A, Moller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol 2003;14:1148-52
207. Curtis RF, DM; Ron, E; Ries, LAG; Hacker, DG; Edwards, BK; Tucker, MA; Fraumeni Jr, JF. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006
208. Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013;62:1523-8
209. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis 2014;20:926-35
210. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24-36
211. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-7
212. Frankenthaler A, Sullivan RJ, Wang W, et al. Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. Melanoma Res 2010;20:496-500
213. Csuka ME, Hanson GA. Resolution of a soft-tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Arch Int Med 1996;156:1573-6
214. Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994;331:883-4
215. Beaugerie L. Management of inflammatory bowel disease patients with a cancer history. Curr Drug Targets 2014;15:1042-8
216. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res [Hoboken] 2010;62:755-63
217. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5
218. Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-22
219. Guerra I, Algaba A, Quintanilla E, et al. Management and course of inflammatory bowel disease patients with associated cancer. J Crohn's Colitis 2014;8:S49
220. Onali S, Petruzziello C, Condino G, et al. Thiopurines and anti-TNFs after a diagnosis of cancer in patients with inflammatory bowel disease. J Crohn's Colitis 2014;8:S107-8
221. Poullenot FS, Beaugerie L, Amiot A, et al. Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years [GETAID survey]. In: 9th ECCO Congress, February 20-22, 2014; Copenhagen
222. Axelrad JE, Fowler SA, Friedman S, et al. Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and Reactivation. Clin Gastroenterol Hepatol 2012;10:1021-27.e1
223. Stobaugh DJ, Deepak P, Ehrenpreis ED. A predictive model of the risk of developing multiple cancers with tumor necrosis factor alpha inhibitor therapy among patients with inflammatory bowel disease. Gastroenterology 2013;1:S410
224. Travis LB, Demark Wahnefried W, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301
225. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8 e1-5
226. Dreier J, Alleman IB, Cheng P, et al. Preliminary data: Basal cell carcinomas in tertiary referral center-a systematic analysis. Journal Der Deutschen Dermatologischen Gesellschaft 2013;11:116-7
227. Sogaard KK, Cronin-Fenton DP, Pedersen L, et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2008;14:519-25
228. Rajca S, Seksik P, Bourrier A, et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis 2014;8:819-24
229. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19
230. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71
231. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008;19:1340-6
232. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-9
233. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients [N01C9]. Lung Cancer 2010;68:234-9
234. Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25
235. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9
236. Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014;48:806-10
237. Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013;23:227-30
238. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, et al. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther 2013;4:80-2
239. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40
240. Lees CW, Ironside J, Wallace WAH, et al. Resolution of non-smallcell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 2008;359:320-1
241. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002;360:1969-70
242. Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009;100:200-5
243. Sorensen GV, Cronin-Fenton DP, Sorensen HT, et al. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res 2012;14:R21
244. Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: A population-based cohort study. J Natl Cancer Inst 2004;96:709-11
245. Bansal P, Lalos A. Case of fulminant colitis after docetaxel therapy for breast carcinoma in a patient with underlying ulcerative colitis. Inflamm Bowel Dis 2011;17:S27-8
246. Burdine L, Lai K, Laryea JA. Ipilimumab-induced colonic perforation. J Surg Case Rep 2014;2014 (3). doi: 10.1093/jscr/rju010
247. Hinds AM, Ahmad DS, Muenster JE, et al. Ipilimumab-induced colitis: a rare but serious side effect. Endoscopy 2014;46 Suppl 1 UCTN:E308-9
248. Loriot Y, Boudou-Rouquette P, Billemont B, et al. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 2008;19:1975
249. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243-6
250. Bhalme M, Hayes S, Norton A, et al. Rituximab-associated colitis. Inflamm Bowel Dis 2013;19:E41-3
251. Dubeau MF, Iacucci M, Beck PL, et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 2013;19:445-56
252. Al-Moundhri MS, Al-Thahli K, Al-Kindy S, et al. Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis. Saudi Med J 2006;27:1585-7
253. Magro F, Costa C. Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2006;12:1087-9